James C. Hamilton Sells 15,000 Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock

Key Points

• Insider James Hamilton sold 15,000 shares of Arrowhead Pharmaceuticals for $450,000, reducing his ownership by 6.07% to 232,122 shares valued at approximately $6.96 million.
• The company's stock price recently hit $29.42, with a significant range over the past year between $9.57 and $31.13.
• Arrowhead Pharmaceuticals reported a loss of $1.26 EPS for the last quarter, missing expectations, and analysts predict a year-end EPS of -$2.42.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) insider James C. Hamilton sold 15,000 shares of the firm's stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $30.00, for a total value of $450,000.00. Following the completion of the sale, the insider directly owned 232,122 shares of the company's stock, valued at $6,963,660. This trade represents a 6.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Arrowhead Pharmaceuticals Stock Down 2.6%

Arrowhead Pharmaceuticals stock traded down $0.82 during mid-day trading on Friday, reaching $30.69. The stock had a trading volume of 4,937,943 shares, compared to its average volume of 2,707,305. The company has a debt-to-equity ratio of 0.39, a quick ratio of 4.87 and a current ratio of 4.87. Arrowhead Pharmaceuticals, Inc. has a fifty-two week low of $9.57 and a fifty-two week high of $31.67. The stock's 50-day simple moving average is $21.17 and its 200-day simple moving average is $16.95. The firm has a market capitalization of $4.24 billion, a PE ratio of -23.98 and a beta of 1.00.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($1.26) EPS for the quarter, missing analysts' consensus estimates of ($0.94) by ($0.32). The business had revenue of $27.77 million during the quarter, compared to analysts' expectations of $29.01 million. During the same period in the previous year, the business earned ($1.38) earnings per share. On average, sell-side analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its position in Arrowhead Pharmaceuticals by 8.4% in the first quarter. Vanguard Group Inc. now owns 13,202,562 shares of the biotechnology company's stock worth $168,201,000 after acquiring an additional 1,018,273 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Arrowhead Pharmaceuticals by 138.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,785,062 shares of the biotechnology company's stock valued at $60,962,000 after buying an additional 2,774,933 shares during the period. Geode Capital Management LLC boosted its position in shares of Arrowhead Pharmaceuticals by 1.0% during the second quarter. Geode Capital Management LLC now owns 2,978,505 shares of the biotechnology company's stock valued at $47,067,000 after buying an additional 28,193 shares during the period. T. Rowe Price Investment Management Inc. boosted its position in shares of Arrowhead Pharmaceuticals by 0.9% during the first quarter. T. Rowe Price Investment Management Inc. now owns 2,528,982 shares of the biotechnology company's stock valued at $32,220,000 after buying an additional 21,686 shares during the period. Finally, Marshall Wace LLP boosted its position in shares of Arrowhead Pharmaceuticals by 3,507.8% during the second quarter. Marshall Wace LLP now owns 2,155,998 shares of the biotechnology company's stock valued at $34,065,000 after buying an additional 2,096,238 shares during the period. Hedge funds and other institutional investors own 62.61% of the company's stock.

Analysts Set New Price Targets

Several brokerages have issued reports on ARWR. HC Wainwright restated a "buy" rating and issued a $80.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, September 2nd. Royal Bank Of Canada reduced their price target on Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an "outperform" rating for the company in a research report on Friday, August 8th. B. Riley upgraded Arrowhead Pharmaceuticals to a "strong-buy" rating in a research report on Monday, August 11th. Wall Street Zen cut Arrowhead Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Friday, July 18th. Finally, TD Cowen upgraded Arrowhead Pharmaceuticals to a "strong-buy" rating in a research report on Monday, July 28th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and two have assigned a Hold rating to the company's stock. According to MarketBeat, Arrowhead Pharmaceuticals presently has an average rating of "Buy" and a consensus price target of $43.14.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.